Stockscreener 앱 받기
1.36
9.93%
-0.15
시간 외 거래:
1.43
0.07
+5.15%
전일 마감가:
$1.51
열려 있는:
$1.51
하루 거래량:
1.77M
Relative Volume:
0.79
시가총액:
$50.90M
수익:
순이익/손실:
$-57.91M
주가수익비율:
-0.9721
EPS:
-1.3991
순현금흐름:
$-38.14M
1주 성능:
-27.27%
1개월 성능:
-25.27%
6개월 성능:
-89.91%
1년 성능:
-80.06%
1일 변동 폭
$1.36
$1.52
1주일 범위
$1.36
$1.88
52주 변동 폭
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
명칭
Tenax Therapeutics Inc
전화
919-855-2100
주소
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.36 | 50.90M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2026-08-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2026-08-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2026-07-28 | 개시 | Canaccord Genuity | Buy |
| 2026-07-22 | 개시 | Evercore ISI | Outperform |
| 2026-06-22 | 개시 | Chardan Capital Markets | Buy |
| 2026-03-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 개시 | Piper Sandler | Overweight |
| 2024-10-24 | 개시 | Leerink Partners | Outperform |
| 2024-10-14 | 개시 | Guggenheim | Buy |
| 2024-09-30 | 개시 | William Blair | Outperform |
| 2017-05-18 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 개시 | MLV & Co | Buy |
| 2014-11-18 | 개시 | WallachBeth | Buy |
모두보기
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
TENX Stock Drifts Lower As Traders Eye Cash Runway - StocksToTrade
TENX Stock Drifts Lower As Traders Watch Tight Range - Timothy Sykes
Sphera Funds Management Discloses 7.09% Stake in Tenax Therapeutics as of September 2026 - Kalkine Media
Call option shares count toward Sphera’s amended stake disclosure in Tenax Therapeutics (TENX). - Stock Titan
EBIT per share of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
A 2.4M-share position in Tenax Therapeutics (TENX) is reported with no sole voting power. - Stock Titan
Tenax Therapeutics To Amend Level-2 Enrollment Criteria - TradingView
Tenax Therapeutics pauses LEVEL-2 enrollment to implement enrichment after Phase 3 LEVEL learnings - TradingView
Tenax Therapeutics, Inc. Provides Update on Tnx-103 Level and Level-2 Clinical Trials - www.marketscreener.com
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Eastern Progress
Independent Director of Tenax Therapeutics Declan Doogan Buys 2,331% More Shares - webull.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to S&P Global BMI Index - marketscreener.com
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX) - GuruFocus
ING Groep NV Exits Tenax Therapeutics Inc (TENX) Position in Ful - GuruFocus
Tenax Therapeutics CFO buys $10,981 in common stock - Investing.com
ING Groep reports zero stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Stock Short Interest Rises to 35.39% - Quiver Quantitative
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com Canada
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com India
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com UK
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - tipranks.com
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Australia
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Nigeria
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Canada
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TE - GuruFocus
One manager just reported a 14% holding in Tenax Therapeutics (TENX) - Stock Titan
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data - timothysykes.com
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? - Yahoo Finance
Sphera Funds Management Boosts Tenax Therapeutics Stake in High-Risk Biotech Bet - GuruFocus
Investment funds tied to Tenax (TENX) 10% owner just bought more stock - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Stock Titan
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - finance.yahoo.com
TENX Downgraded by Guggenheim -- Rating Updated to Neutral - GuruFocus
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Guggenheim Downgrades TENX to Neutral Amid Uncertain Clinical Ou - GuruFocus
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com Canada
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com UK
Tenax Therapeutics (TENX) Phase 3 Data Spurs Focus on Subgroup B - GuruFocus
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss (TENX:NASDAQ) - Seeking Alpha
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com Nigeria
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com India
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Investing News Network
Tenax Therapeutics Inc (TENX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tenax Therapeutics Inc 주식 (TENX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Giordano Christopher Thomas | CEO |
Sep 15 '26 |
Buy |
1.82 |
4,850 |
8,837 |
22,174 |
| Giordano Christopher Thomas | CEO |
Sep 11 '26 |
Buy |
1.88 |
6,000 |
11,250 |
17,324 |
| STAAB THOMAS R II | Chief Financial Officer |
Sep 11 '26 |
Buy |
1.94 |
5,675 |
10,981 |
15,675 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 03 '26 |
Buy |
1.78 |
900,000 |
1,604,160 |
6,524,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 02 '26 |
Buy |
1.80 |
187,704 |
337,586 |
5,624,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 01 '26 |
Buy |
1.80 |
179,058 |
321,570 |
5,436,447 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 31 '26 |
Buy |
1.79 |
403,571 |
722,594 |
5,257,389 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 24 '26 |
Buy |
1.75 |
107,374 |
188,355 |
4,853,818 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 21 '26 |
Buy |
1.77 |
716,369 |
1,266,254 |
4,746,444 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 20 '26 |
Buy |
1.78 |
202,124 |
359,538 |
4,030,075 |
4.22%
자본화:
|
볼륨(24시간):